Locarpin-F

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Locarpin-F

Property Description
Active Ingredient Pilocarpine Hydrochloride
Form Ophthalmic Solution (Eye Drop)
Pharmacological Class Cholinergic Agonist, Parasympathomimetic Agent
General Purpose Reduction of Intraocular Pressure
Origin Derived Alkaloid

What Type of Medicine is Locarpin-F?

Locarpin-F is a specific pharmaceutical product formulated as a sterile Ophthalmic Solution and is classified as a Prescription Only medication. The product is a single-ingredient product designed for targeted topical ocular use, ensuring its active compound is delivered directly to the eye's front structures. The Locarpin-F brand specifically uses an aqueous base for its eye drop formulation, supporting quick application and dispersal across the ocular surface. Its availability is typically focused on adult patient groups managing chronic eye conditions.

Active Ingredient and Pharmacological Classification

The core component responsible for the therapeutic action in Locarpin-F is Pilocarpine Hydrochloride, an Active Ingredient recognized for its clinical efficacy in ocular therapeutics. Pilocarpine is classified scientifically as a Cholinergic Agonist, which is a type of Parasympathomimetic Agent. Pilocarpine itself is a Derived Alkaloid, a substance initially sourced from plants and then purified and stabilized as a hydrochloride salt for pharmaceutical use. This chemical profile differentiates its action from agents that target other receptor systems in the eye.

General Purpose and High-Level Action

Locarpin-F functions fundamentally as a Miotic agent, causing the pupil to constrict, a process known as miosis. This muscle action simultaneously facilitates the opening of fluid pathways within the eye, significantly enhancing the drainage of the internal fluid known as Aqueous Humor. This effect is consistently utilized to reduce the pressure inside the eyeball, establishing it as an effective Antiglaucoma Agent. For instance, it is typically employed in situations where patients require long-term management of high intraocular pressure. The clinical recognition of Pilocarpine’s pressure-reducing effects is well-established across multiple authoritative medical bodies.

Regulatory References

  1. NIH/NLM/DailyMed: Pilocarpine Ophthalmic
  2. MedlinePlus: Pilocarpine Eye Drops
Advertisements

What side effects are possible with Locarpin-F?

Possible Side Effects and Safety Information

Locarpin-F, which contains Pilocarpine Hydrochloride, has an official safety profile structured by the occurrence and physiological grouping of adverse reactions, as documented in government regulatory sources.

Adverse Reactions by Frequency and System-Organ Class

The safety profile is characterized primarily by ocular adverse reactions due to its targeted topical application. These are generally classified as common or very common and affect the Eye Disorders System-Organ Class. Such effects include miosis (pupil constriction), ciliary spasm (difficulty focusing), blurred vision, eye pain, stinging, and conjunctival injection (redness).

Systemic adverse effects, such as headache, nausea, vomiting, diarrhea, and increased sweating, are also documented, categorized under Nervous System and Gastrointestinal Disorders, but are typically less frequent with the ophthalmic solution.

Time-related patterns note that symptoms like headache and stinging are often more common at the start of treatment or during initial adjustments, and may be transient.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents list the potential for serious adverse reactions, including retinal detachment and iritis, particularly in individuals with pre-existing ocular conditions. Therefore, caution is advised for patients with existing retinal disease.

Locarpin-F is contraindicated and should not be used in individuals with pre-existing acute inflammatory disease of the anterior segment of the eye (like acute iritis) or in patients with pupillary block glaucoma, as specified in the official prescribing information. The medication may also cause visual impairment in low light, a constraint related to its use.

Advertisements

Overdose and Emergency Response

Locarpin-F Overdose and when to seek help

This section details the officially documented overdose profile for Locarpin-F (Pilocarpine Hydrochloride Ophthalmic Solution), based strictly on government regulatory documentation.

Property Description (Regulatory Statement)
Documented Overdose Presentations Systemic manifestations of cholinergic toxicity are the expected presentation from overexposure. These include signs of excessive glandular secretion (salivation, lacrimation, sweating) and gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal cramps).
Physiological Systems Affected Severe systemic overexposure affects the Cardiovascular System (potential for bradycardia, hypotension, and cardiac arrhythmias), the Respiratory System (risk of bronchospasm and potentially pulmonary edema), and the Central Nervous System (risk of seizures).
Emergency Actions Required Immediate medical attention must be sought if overexposure is suspected or confirmed. Regulatory guidance mandates contacting a Poison Control Center or emergency medical services for management instructions.
Antidote and Management A specific antidote, Atropine, is documented for use in managing severe systemic effects. Treatment is symptomatic and supportive, requiring continuous hospital monitoring and observation to manage life-threatening complications.

Connection to the overall overdose profile: Official regulatory documents define the overdose profile by outlining the progression from common systemic cholinergic signs to severe, potentially life-threatening cardiovascular and respiratory complications. This serious risk profile necessitates that the labeling mandate the immediate action to seek professional medical attention and contact emergency services. The documents further specify that management requires specialized symptomatic support, continuous observation, and the use of the officially documented specific antidote.

Advertisements

Therapeutic Uses of Locarpin-F

What Locarpin-F Treats: Main Uses and Benefits

Locarpin-F is generally used in situations involving certain distressing symptoms linked to organ-specific functional stress, where additional symptomatic support is needed. Its application is relevant for easing the overall symptom burden tied to managing pressure.

The medication is commonly used across conditions presenting with acute episodes and recurrent manifestations, including open-angle glaucoma, ocular hypertension, and the acute angle-closure crisis. It also assists with managing symptoms related to the clinical requirement for pupil constriction (miosis).

“Locarpin-F provides support that helps ease the overall symptom burden by contributing to improved comfort during periods of heightened symptoms.”

Management of Eye Pressure and Visual Stability

Locarpin-F is applied across domains where additional symptomatic support is needed to control the fluid pressure that creates noticeable physiological strain. In chronic contexts, it helps maintain a sense of stability for visual function over time and is generally used to help manage the overall symptom load. When symptoms intensify and supportive relief is needed, such as during an acute crisis, the medication may assist with the rapid reduction of pressure. This supports patients during episodes of heightened discomfort by offering symptomatic relief.


Quick Fact: Relief for Elevated Intraocular Pressure Its use contributes to easing the overall symptom load by providing support that helps manage the fluid pressure inside the eye, which assists with maintaining functional stability and is relevant for easing the burden of chronic eye conditions.

Regulatory References

  1. NIH DailyMed drug information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Locarpin-F — Official Regulatory Information

The eligibility for Locarpin-F (Pilocarpine Ophthalmic Solution) is strictly defined in regulatory documents based on patient status, age, and existing medical conditions.


Contraindicated Populations (Absolute Non-Eligibility):

Classification Non-Eligible Population Regulatory Basis
Absolute Prohibition Patients with known hypersensitivity to Pilocarpine Hydrochloride or any excipients in the product. FDA/EMA
Absolute Prohibition Patients with Active Anterior Uveitis (acute iritis) or conditions where pupillary constriction (miosis) is undesirable. NIH/DailyMed

Age-Related and Conditional Use Restrictions:

Category Regulatory Status Status Notes
Adults & Older Adults Established Use is generally approved; no overall differences in safety noted in older adults.
Pediatric Patients Established/Restricted Use is established for certain glaucoma indications, but not recommended for specific subtypes (e.g., glaucoma secondary to uveitis).
Pregnancy Use only if clearly needed Lack of adequate, well-controlled human studies mandates conditional use.
Lactation (Breastfeeding) Caution Advised It is unknown if the drug is excreted into human milk.

Comorbidity-Linked Eligibility Restrictions:

  • Pre-existing Retinal Disease: Caution is advised, and a thorough retinal examination is recommended prior to initiation of therapy due to the documented risk of retinal detachment with miotics.
  • Systemic Conditions: Caution is advised in patients with underlying issues such as bronchial asthma or peptic ulceration, due to potential for systemic cholinergic effects.
  • Iritis: Use is not recommended when iritis is present due to the potential for forming synechiae (adhesions).

Connection to the overall eligibility profile: Regulatory documents establish the eligibility profile by prohibiting use in patients with hypersensitivity or acute ocular inflammation, while confirming eligibility for adults. Conditional use statements govern the use in specific populations, such as those with retinal disease or during pregnancy, emphasizing that use must be within the parameters of the official labeling.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Locarpin-F (Pilocarpine Hydrochloride Ophthalmic Solution) is strictly defined by official regulatory documentation, focusing on its targeted ophthalmic use and low level of systemic absorption. Interactions are categorized based on effects on eye pressure and administration requirements.

Interactions with Anti-Glaucoma Agents

Locarpin-F is officially permitted for co-administration with specific classes of anti-glaucoma agents. This combination results in a pharmacodynamic reinforcement, which is an officially documented additive effect in lowering intraocular pressure. This includes co-use with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics, and hyperosmotic agents. No combination is explicitly listed as a contraindicated drug-drug interaction in the official labels.

Mandatory Administration Timing

A strict procedural requirement, known as an administration-timing constraint, applies to all concurrent topical ocular therapy. If Locarpin-F is used alongside any other topical ophthalmic product, the medicines must be administered with a mandatory separation period of at least five (5) minutes. This rule is required to ensure the proper retention and efficacy of each medication on the ocular surface.

Systemic and Other Interactions

Due to the minimal systemic exposure from the ophthalmic route, official regulatory documents do not list specific pharmacokinetic interactions involving major systemic metabolic pathways, such as those related to CYP enzymes or drug transporters. Furthermore, official prescribing information does not document any interactions with food, alcohol, or herbal products for this eye drop formulation.

Advertisements

Mechanism of Action

How Locarpin-F Works


Locarpin-F's mechanism of action is based on direct cholinergic agonism, where its active component binds to and activates Muscarinic Acetylcholine Receptors ( M3 subtype) located on the smooth muscle of the anterior eye segment. This targeted receptor binding initiates the sustained contraction of the ciliary muscle and enhances the local parasympathetic tone, which is the initial step in the physiological cascade.

This molecular action translates into a crucial physical consequence: the ciliary muscle's contraction mechanically pulls on the Trabecular Meshwork (TM) structure. This pulling physically widens the fluid pathways, leading to an increase in the facility of Aqueous Humor drainage. This mechanism directly influences the dynamics of intraocular pressure within the eyeball.

Simultaneously, the same receptor activation causes the iris sphincter muscle to contract, resulting in miosis (pupil constriction). However, the overall physiological capacity of this mechanism is constrained by the structural integrity of the outflow pathway; if the M3 target tissues are ischemic or permanently scarred, the mechanism's capacity for increasing fluid outflow is diminished or completely blocked.

Advertisements

Dosage and Administration Information

How to Use Locarpin-F

Locarpin-F is an Ophthalmic Solution administered solely through topical ocular instillation. This approach ensures the delivery of the active component, Pilocarpine, directly to the eye's structures, consistent with its available concentrations of 1%, 2%, and 4%. The medicine’s usage patterns are defined by the therapeutic goal, dictating a highly structured frequency and specific administration conditions.


Official Usage Patterns and Dosing

Feature Official Labeled Instruction
Route of Administration Topical Ocular Instillation (Eye Drops).
Standard Dose One drop per affected eye per administration.
Maintenance Frequency Up to four times daily (QID) for chronic pressure management.
Acute Use Frequency Short-term use, such as one drop of 1% or 2% solution up to three times over a 30-minute period for acute angle-closure crisis.
Strength Adjustment Strength may begin at 1% and be titrated up to 4% for maintenance, depending on established protocols.

Procedural Administration Requirements

The correct application of Locarpin-F involves specific procedural steps documented in official labeling to maintain sterility and ensure proper absorption. All topical ophthalmic products, if co-administered, must be separated by at least five minutes to avoid washing out the preceding dose. Contact lenses must be removed prior to instillation and should not be reinserted for at least 10 minutes afterward. Following drop administration, gentle pressure (punctual occlusion) applied to the tear duct for approximately two minutes is specified to help limit systemic exposure.

Population-Specific Use

Official labeling addresses use in specific populations; for example, specific dosing protocols are detailed for pediatric patients under two years of age, such as a lower frequency of one drop of 1% solution three times daily for intraocular pressure reduction.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Locarpin-F

Research has evaluated the active ingredient for chronic elevated eye pressure in adults diagnosed with Open-Angle Glaucoma or Ocular Hypertension. Studies were conducted to monitor the measured Intraocular Pressure (IOP) over time, including short-term randomized controlled trials (RCTs) and observational settings evaluating patterns over longer periods. These studies examined outcomes related to physiological strain or stress, specifically measuring the absolute IOP and the consistency of pressure control. The clinical literature includes historical evidence supporting this evaluation. However, comparative evidence against all newer therapeutic alternatives is limited in recent large-scale RCTs, and the methodology of older studies often differed across the research landscape.

Evidence for Improving Near Visual Acuity

More recent research has evaluated the active ingredient for near visual acuity in presbyopia in adults (typically ages 40–60). Researchers used large-scale, randomized, double-masked trials to monitor patient-reported outcomes and the percentage of participants whose near visual acuity (DCNVA) changed over defined time intervals. Trials reported that a percentage of the observed populations described patterns such as a measured change in near vision compared to the control group. The measured effect on vision was observed to be temporary and assessed over short intervals after each application.

Research Gaps and Limitations

The evidence base is extensive for chronic eye pressure but is newer for near vision. Long-term effects are not fully established for the lower concentration use in presbyopia, as follow-up durations were limited in the key registration trials for that indication. Data for certain groups, such as children, pregnant women, and populations with specific comorbidities, remain insufficient as these groups are commonly excluded from the initial randomized trials. The evidence for use in acute pressure spikes relies heavily on clinical consensus and historical practice, rather than modern RCTs.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Locarpin-F (FAQ)


Q: How long does the effect of one dose of Locarpin-F typically last?

A: The length of time one dose of Locarpin-F remains active can vary based on its formulation. Studies examining the temporary effect on near vision have assessed changes over short intervals, with some regulatory data suggesting the effect may last up to 8 hours. Regulatory data on pharmacokinetics indicates the substance concentration in the body has been measured to reach its highest level within a range of 0.3 to 2.2 hours after administration.


Q: Is it necessary to take Locarpin-F with food?

A: No. Locarpin-F is an eye drop solution administered only to the eye. Official regulatory documents do not specify any procedural requirement to administer the eye drops in relation to food or meals.


Q: Is Locarpin-F the same type of medicine as [Name of known competitor or class]?

A: The active component in Locarpin-F is classified by regulatory authorities as a cholinergic muscarinic receptor agonist. This means the medicine works by activating specific nerve receptors in the eye. The specific classification may be a topic for discussion with a healthcare provider.


Q: Can Locarpin-F be taken long-term?

A: The medicine is indicated for the management of chronic conditions like glaucoma. This therapeutic goal typically involves sustained use. However, the evidence base notes that long-term effects for certain uses, such as presbyopia, are not fully established in all key registration trials.


Q: Does Locarpin-F have a risk of dependency?

A: Regulatory sources classify the active ingredient in Locarpin-F as not being a controlled substance. This classification indicates that the medicine is not assessed to have the potential for abuse or dependency that would require it to be a controlled substance.


Q: Are there any dietary restrictions while using Locarpin-F?

A: No. Official prescribing information for this eye drop formulation does not document any specific interactions or restrictions related to diet or food that patients must follow.


Q: Can a senior citizen use Locarpin-F?

A: Locarpin-F is indicated for use in adults. Regulatory information notes that individuals in the older age group may frequently experience reduced visual acuity in poor illumination (low-light conditions) when using the medicine.


Q: Is Locarpin-F safe for children?

A: Official labeling addresses the use of the medicine in pediatric patients. Official protocols for children 2 years of age and over often follow the general usage patterns described for adults. Specific usage protocols are detailed for children under 2 years of age in official prescribing information.


Q: What happens if I miss a dose of Locarpin-F?

A: Regulatory patient information advises using the eye drop as soon as remembered if a dose is missed. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. It is advised not to use double or extra doses to compensate for a missed one.


Q: Do studies support the intended use of Locarpin-F?

A: Studies and research evidence support the medicine's two main indications. Clinical trials have examined outcomes related to measured intraocular pressure (IOP) and measured near visual acuity in adults with presbyopia.


Q: Is Locarpin-F available without a prescription?

A: Official information confirms that Locarpin-F is a prescription-only medication.


Q: Can Locarpin-F be used with over-the-counter painkillers?

A: Official regulatory documents do not list specific interactions between the eye drop formulation and major systemic medications, such as common over-the-counter painkillers.


Q: Does Locarpin-F interact with vitamins or herbal supplements?

A: No. Official prescribing information for the eye drop formulation does not document any specific interactions with vitamins or herbal products.


Q: What is the safety rating of Locarpin-F in pregnancy?

A: Due to a lack of adequate human data, the US risk summary states that use during pregnancy should be considered only if clearly needed. The active ingredient has been noted to be categorized as B3 by the Australian Therapeutic Goods Administration (TGA).


Q: Is there a generic version of Locarpin-F?

A: Yes. The active ingredient found in Locarpin-F is available as a generic product, which is often offered as a lower-cost option compared to the branded version.


Q: What is the pharmacological class of Locarpin-F?

A: Regulatory documents classify the medicine as a cholinergic muscarinic receptor agonist. This means its mechanism of action involves activating specific muscarinic receptors on the eye's smooth muscle.


Q: Are there studies that look at Locarpin-F in diverse patient groups?

A: The evidence base for the medicine is not fully established for all patient groups. Regulatory documents note that data for certain groups, such as children, pregnant women, and populations with specific comorbidities, is often insufficient as these groups are commonly excluded from initial randomized trials.


Q: What serious side effects are listed for Locarpin-F?

A: Regulatory documents describe the serious adverse reactions associated with the medicine. These include retinal detachment and iritis (inflammation of the colored part of the eye), particularly in individuals with pre-existing ocular conditions.


Q: Can Locarpin-F affect driving or operating machinery?

A: Yes, official regulatory labeling addresses this. It is advised that individuals should not drive or use machinery if vision is not clear, which may include temporary blurred vision after instillation. Caution is specifically advised with night driving or hazardous activities in poor illumination.


Q: Does Locarpin-F build up in the body over time?

A: Pharmacokinetic data indicates the active ingredient has a measurable half-life of approximately 4 hours. This half-life provides context for how quickly the body processes and clears the substance within a defined period after each dose.


Q: Has the manufacturer issued any public safety alerts about Locarpin-F?

A: Regulatory information provides clear contact details for patients to report suspected adverse reactions. Cautionary safety information has been issued concerning a potentially heightened risk of retinal detachment for its use in presbyopia.


Q: Is it possible to have an allergic reaction to Locarpin-F?

A: Yes. Regulatory documents list a known hypersensitivity (an allergic reaction) to the active ingredient or to any of the inactive components (excipients) as a contraindication to using the medicine.


Q: Does Locarpin-F interact with alcohol?

A: No. Official prescribing information for this eye drop formulation does not document any specific interactions with alcohol.


Q: Is there an age limit for who can use Locarpin-F?

A: Official labeling addresses the use of the medicine in pediatric patients, setting a minimum age threshold. Specific usage protocols are detailed for children under 2 years of age and for children 2 years of age and older.


Q: What research evidence supports the use of Locarpin-F?

A: Research evidence supports the medicine’s two main indications. This includes studies for the reduction of elevated intraocular pressure in patients with glaucoma and studies focused on measured changes in near visual acuity in patients with presbyopia.


Q: Can Locarpin-F be used if I have a chronic condition other than what it treats?

A: Regulatory guidance advises caution when using the medicine in patients with pre-existing ocular conditions. Regulatory guidance includes specific mention of caution regarding use in the presence of pre-existing ocular conditions such as retinal disease or acute inflammatory disease of the eye.


Q: How long after stopping Locarpin-F are drug effects cleared from the body?

A: The active ingredient has a measurable half-life of approximately 4 hours, based on pharmacokinetic data. This information provides context for how quickly the substance is processed and cleared from the body after stopping use.


Q: Does Locarpin-F affect blood pressure?

A: Although uncommon with topical administration, regulatory documents note that systemic adverse effects have included reports of hypertension (high blood pressure) and tachycardia (fast heart rate).


Q: Are there known interactions between Locarpin-F and grapefruit?

A: No. Official prescribing information for this eye drop formulation does not document any specific interactions with food, or dietary products like grapefruit.


Q: Are there any contraindications listed for people with heart disease?

A: Contraindications (reasons the drug should not be used) are officially listed as a known hypersensitivity, acute inflammatory disease of the anterior segment of the eye, and pupillary block glaucoma. Heart disease is not listed as a contraindication.


Q: How can I tell if a minor side effect requires contacting a healthcare provider?

A: Official patient information advises seeking immediate medical care if you experience a sudden onset of flashing lights, floaters, or vision loss, as these may indicate a serious problem. For minor side effects, official patient information indicates that contacting a healthcare provider is appropriate if the minor effects bother the patient or do not resolve.

Advertisements

How should Locarpin-F be stored and disposed of?

Official Storage and Disposal Requirements for Locarpin-F

Locarpin-F (Pilocarpine Hydrochloride Ophthalmic Solution) must be stored strictly according to the conditions mandated by regulatory labeling to maintain its stability and sterility.


Storage Conditions

The medicine requires storage at controlled room temperature, specifically between 15 C to 25 C (59 F to 77 F). The product must be protected from freezing at all times. To prevent contamination, users must avoid touching the dropper tip of the container to any surface, including the eyelid.

Safety and Disposal

Locarpin-F must be stored out of reach of children. For formulations supplied in single-patient-use vials, the labeling requires that the vial must be discarded immediately after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Locarpin-F found in:

A-Z Index: